Hasil Pencarian  ::  Simpan CSV :: Kembali

"Mual dan muntah merupakan hal yang mengkhawatirkan bagi pasien sebagai efek samping dari penggunaan kemoradioterapi. Antiemetik dari golongan antagonis reseptor 5HT3 adalah terapi antiemetik standard yang digunakan dalam penanganan mual dan muntah yang disebabkan kemoradioterapi. Penelitian ini bertujuan untuk mengetahui gambaran penggunaan antiemetik yang menyertai pemberian kemoradioterapi serta faktor-faktor yang mempengaruhi keadaan pasien pasca kemoradioterapi.Penelitian dilakukan terhadap pasien kanker serviks di RS Kanker Dharmais pada periode Januari 2004 - Nopember 2006 dengan menggunakan desain cross sectional dan bersifat retrospektif dan dengan cara observasional.Hasil penelitian menunjukkan tidak ada hubungan bermakna antara usia pasien, stadium kanker, jenis kemoterapi, seri kemoradioterapi, dan jenis antiemetik dengan keadaan pasien pasca kemoradioterapi (p > 0,05).

---

Nausea and vomiting are two of the most feared side effect of cancer chemoradiotherapy. The 5HT3 receptor antagonist is grouped as antiemetic standar therapy for handling nausea and vomiting caused by chemoradiotherapy. This research focus in exploring knowledge the use of antiemetics drugs in a chemoradiotherapy and its factors which influences the patient after therapy treatments.

Research has been conducted in Dharmais Cancer Hospital for servical cancer patient in period January 2004 - November 2006 using cross sectional design in the way retrospectively and observation.

The results show that there is no relation between the age of the patient, cancer stadium, chemotherapy type, chemoradiotherapy series, and antiemetic type with the patient condition pasca chemotheraphy (p > 0,05)."

"Latar belakang: Sebagian besar pasien kanker usia lanjut terdiagnosis pada stadium lanjut dengan peningkatan risiko mortalitas. Identifikasi faktor prediktor yang memengaruhi terjadinya mortalitas satu tahun diharapkan dapat membantu stratifikasi risiko dan menjadi pertimbangan perencanaan pelayanan kesehatan, edukasi, serta persiapan advanced care planning.Tujuan: Mengetahui faktor prediktor mortalitas satu tahun pada lansia dengan kanker padat metastasis dan mengembangkan model prediksi mortalitas satu tahun.Metode: Studi kohort retrospektif dengan menelusuri rekam medis pasien berusia ≥60 tahun dengan kanker padat metastasis berdasarkan pemeriksaan histopatologi atau radiologi yang berobat di poli onkologi RS Kanker Dharmais pada Januari 2020 hingga Desember 2021. Dilakukan analisis bivariat chi-square antara usia, jenis kelamin, ADL, ECOG-PS, jenis kanker, metastasis organ, jumlah metastasis, status nutrisi, komorbid, jumlah komorbid, polifarmasi, gangguan kognitif, gangguan mood, dan best supportive care dengan mortalitas satu tahun sesudah diagnosis kanker metastasis. Analisis multivariat dan model prediksi dilakukan dengan regresi logistik.Hasil: Terdapat 210 subjek dengan hasil analisis bivariat menunjukkan hubungan antara ECOG-PS, status nutrisi, dan pemberian best supportive care dengan mortalitas satu tahun (p<0,05). Hasil regresi logistik menunjukkan faktor prediktor independen mortalitas yaitu metastasis organ (OR 2,468 [IK 95%1,163-5,317]), status nutrisi (OR 1,943 [IK 95%1,048-3,604]), ECOG-PS (OR 2,302 [IK 95%1,241-4,271]), dan best supportive care (OR 3,157 [IK 95%1,288-7,738]). Model prediksi mortalitas satu tahun memiliki nilai AUC 0,705 (IK 95%95%: 0,629 – 0,781).Kesimpulan:Faktor prediktor independen terhadap mortalitas 1 tahun sesudah diagnosis metastasis yaitu metastasis organ, ECOG-PS, status nutrisi, dan best supportive care.

---

Background: Identification of patients on their final year is important to help physicians to make personalized treatment plan according to life expectancy and to guide patients and families to prepare an advanced care planning.

Methods: We retrospectively included patients aged ≥60 years who had metastatic solid cancer and in whom geriatric assessment was performed in Dharmais National Cancer Center outpatient clinic. A total of 210 subjects were enrolled between January 2020 to December 2021. The primary analyses were performed from April to May 2023. Chi square analysis was performed between age, sex, ADL, ECOG-PS, type of cancer, visceral metastasis, number of metastatic sites, nutritional status, comorbidity, multimorbidity, polypharmacy, cognitive impairment, mood disorder, and best supportive care with one-year mortality. Variables with p value <0.25 were analysed further with logistic regression to develop a prediction model. The model’s discriminative ability was assessed with model’s area under the curve. Calibration was performed using bootstrap method.

Result: We collected 210 subjects, with median age, 66,5 years. Lung cancer was the most common malignancy (44.3%). Logistic regression results showed visceral metastasis (OR 2.468; 95% CI 1.163-5.317), nutritional status (OR 1.943; 95% CI 1.048-3.604), ECOG-PS (OR 2.302; 95% CI 1.241-4.271), and best supportive care (OR 3.157; 95% CI 1.288-7.738) were independent predictors of one year mortality. The one-year mortality prediction model has an AUC value of 0.705 (95% CI: 0.629-0.781).

Conclusion: Model developed from this study can assist clinicians to identify patients in their last year of life who need palliative care and to prepare an advance care planning. "

"Latar Belakang: Leukemia Granulositik Kronik (LGK) fase kronik merupakan salah satu penyakit keganasan hematologi yang diagnosis definitifnya ditegakkan menggunakan pemeriksaan baku emas sitogenetika untuk mendeteksi Kromosom Philadelphia dan/ atau Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) BCR-ABL untuk mendeteksi transkrip gen BCR-ABL. Berdasarkan pengamatan, pasien-pasien LGK fase kronik di Poliklinik Hematologi-Onkologi Medik Departemen Ilmu Penyakit Dalam RSUPN dr. Cipto Mangunkusumo yang telah menjalani pemeriksaan sitogenetika dan/ atau RT-PCR BCR-ABL akan menunjukkan: LGK Ph (+)/ BCR-ABL (+) dan LGK bentuk kelainan Ph/ BCR-ABL lainnya. Tujuan: Mengetahui gambaran klinis dan laboratorium hematologis LGK fase kronik, proporsi LGK Ph(+)/BCR-ABL(+), serta bagaimana perbandingan dan hubungan gambaran klinis dan laboratorium hematologis antara LGK Ph (+)/ BCR-ABL (+) dengan LGK bentuk kelainan Ph/ BCR-ABL lainnya. Metode: Studi potong lintang. Sampel penelitian diambil dengan metode consecutive. Analisis menggunakan uji Chi-square dan regresi logistik. Hubungan antar variabel dinyatakan bermakna apabila nilai p<0,05. Hasil: Dari 80 subjek LGK fase kronik: rerata usia 39,4 ± 13,1 tahun. Perbandingan pria : wanita = 1 : 1. Keluhan subjek yang simtomatik : asimtomatik = 83,8% : 16,2%. Keluhan yang simtomatik adalah: perut bengkak, lemas, begah, keringat malam, dan benjolan di perut. Pemeriksaan fisik splenomegali : limpa tidak teraba = 83,8% : 16,2%. Pemeriksaan laboratorium hematologis menunjukkan: rerata kadar Hb adalah 10,6 ± 1,7 g/dL, median jumlah leukosit adalah 125.710 /uL, dan median jumlah trombosit adalah 470.000/uL. Proporsi LGK Ph (+)/ BCR-ABL (+) mencapai 90%. Perbandingan gambaran klinis dan laboratorium hematologis antara LGK Ph (+)/ BCR-ABL (+) dan LGK bentuk kelainan Ph/ BCR-ABL lainnya adalah sebagai berikut: keluhan yang simtomatik 80,6% : 100 %, Splenomegali 82% : 92,3%, Median Hb 10,3 g/dL : 10,3 g/dL, Median leukosit 124.620 : 127.050, Median Trombosit 455.000 : 487.000. Hasil analisis bivariat dan multivariat menunjukkan tidak ada variabel gambaran klinis dan laboratorium hematologis yang berhubungan bermakna antara LGK Ph (+)/ BCR-ABL (+) dengan LGK bentuk kelainan Ph/ BCR-ABL lainnya. Kesimpulan: Tidak ada variabel gambaran klinis dan laboratorium hematologis yang berhubungan bermakna antara LGK Ph(+)/ BCR-ABL(+) dengan LGK bentuk kelainan Ph/ BCR-ABL lainnya.

---

Background: Chronic myeloid leukemia (CML) is one of hematological malignancy in which the gold standard of definitive diagnosis is established by cytogenetic to detect Philadelphia chromosome and Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) to detect the BCR-ABL gene transcript. Based on observation, patients with chronic phase CML at policlinic Hematology-Medical Oncology Department of Internal Medicine dr. Cipto Mangunkusumo National Hospital who have been performed cytogenetic and RT-PCR BCR-ABL examination showed: Ph (+)/ BCR-ABL (+) CML and other type of Ph/ BCR-ABL CML.

Aims: To recognize the clinical features and hematological laboratories of chronic phase CML, the proportion of Ph (+)/ BCR-ABL (+) CML, and comparison & association of clinical features and hematological laboratories between Ph (+)/ BCR-ABL (+) CML and other type of Ph/ BCR-ABL CML.

Method: This is a cross-sectional study. The samples were taken by consecutive method. We used Chi-square test and logistic regression analysis. Association between variables considered significant when p value < 0.05.

Result: There were 80 subjects with chronic phase CML. Mean of age was: 39,4 ± 13,1 years. Ratio male : female = 1 : 1. Ratio symptomatic : asymptomatic = 83,8% : 16,2%. The symptoms of chronic phase CML were: abdominal swelling, fatigue, abdominal bloating, night sweat, and abdominal lump. The vast majority of subjects with chronic phase CML revealed splenomegaly (83,8%). Hematological laboratory showed: mean of Hb level was 10,6 ± 1,7 g/dL, median of white blood cell count was 125.710 /uL, and median of platelet count was 470.000/uL. The proportion of Ph (+)/ BCR-ABL (+) CML was up to 90%. The comparison of clinical features and hematological laboratories between Ph (+)/ BCR-ABL (+) CML and other type of Ph/ BCR-ABL CML were: Simptomatic features 80,6% : 100%, Splenomegaly 82% : 92,3%, Median of Hb 10,3 g/dL : 10,3 g/dL, Median of white blood cell 124.620 : 127.050, Median of thrombocyte 455.000 : 487.000. Bivariate and multivariate analysis showed no significant variables both clinical features and hematological laboratories between Ph (+)/ BCR-ABL (+) CML and other type of Ph/ BCR-ABL CML.

Conclusion: There were no variables both clinical features and hematological laboratories have a significant relationship between Ph (+)/ BCR-ABL (+) CML and other type of Ph/ BCR-ABL CML."